These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 1426320

  • 1. A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization.
    San Roman GA, Surrey ES, Judd HL, Kerin JF.
    Fertil Steril; 1992 Oct; 58(4):744-9. PubMed ID: 1426320
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Short-term endocrine response to gonadotropin-releasing hormone agonist initiated in the early follicular, midluteal, or late luteal phase in normally cycling women.
    Gelety TJ, Pearlstone AC, Surrey ES.
    Fertil Steril; 1995 Dec; 64(6):1074-80. PubMed ID: 7589655
    [Abstract] [Full Text] [Related]

  • 4. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
    Minaretzis D, Alper MM, Oskowitz SP, Lobel SM, Mortola JF, Pavlou SN.
    Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
    [Abstract] [Full Text] [Related]

  • 5. Incomplete androgen and progesterone suppression following midluteal GnRHa prior to controlled ovarian hyperstimulation for IVF-ET.
    Gelety TJ, Surrey ES.
    J Assist Reprod Genet; 1997 Oct; 14(9):525-30. PubMed ID: 9401871
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT, Ohlinger R.
    Eur J Obstet Gynecol Reprod Biol; 2006 May 01; 126(1):87-92. PubMed ID: 16377065
    [Abstract] [Full Text] [Related]

  • 8. Increased progesterone/estradiol ratio in the late follicular phase could be related to low ovarian reserve in in vitro fertilization-embryo transfer cycles with a long gonadotropin-releasing hormone agonist.
    Younis JS, Matilsky M, Radin O, Ben-Ami M.
    Fertil Steril; 2001 Aug 01; 76(2):294-9. PubMed ID: 11476775
    [Abstract] [Full Text] [Related]

  • 9. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger.
    Derksen L, Tournaye H, Stoop D, Van Vaerenbergh I, Bourgain C, Polyzos NP, Haentjens P, Blockeel C.
    Reprod Biomed Online; 2014 Mar 01; 28(3):359-68. PubMed ID: 24456700
    [Abstract] [Full Text] [Related]

  • 10. Luteal phase consequences of low-dose gonadotropin-releasing hormone agonist therapy in nonluteal-supported in vitro fertilization cycles.
    Long CA, Sopelak VM, Lincoln SR, Cowan BD.
    Fertil Steril; 1995 Sep 01; 64(3):573-6. PubMed ID: 7641913
    [Abstract] [Full Text] [Related]

  • 11. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C.
    Fertil Steril; 2008 Jan 01; 89(1):84-91. PubMed ID: 17462639
    [Abstract] [Full Text] [Related]

  • 12. The efficacy of a combination administration of gonadotropin-releasing hormone agonist and gonadotropins for controlled ovarian hyperstimulation in IVF program.
    Chang YS, Kim SH, Shin CJ, Kim JG, Moon SY, Lee JY.
    Asia Oceania J Obstet Gynaecol; 1990 Dec 01; 16(4):337-45. PubMed ID: 2129188
    [Abstract] [Full Text] [Related]

  • 13. Gonadotropin-releasing hormone and its analogues: applications in gynecology.
    Garcia JE.
    Clin Obstet Gynecol; 1993 Sep 01; 36(3):719-26. PubMed ID: 8403618
    [Abstract] [Full Text] [Related]

  • 14. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM, Polyzos NP, van Vaerenbergh I, Bourgain C, Blockeel C, Alsbjerg B, Papanikolaou EG, Humaidan P.
    Fertil Steril; 2013 Sep 01; 100(3):742-7. PubMed ID: 23806846
    [Abstract] [Full Text] [Related]

  • 15. The effects of gonadotropin-releasing hormone agonist on androstenedione production and follicular development during controlled ovarian hyperstimulation.
    Akaboshi K, Oda T, Yoshida J, Kohriyama S, Miyazaki T, Yoshimura Y.
    J Assist Reprod Genet; 1998 Sep 01; 15(8):478-84. PubMed ID: 9785195
    [Abstract] [Full Text] [Related]

  • 16. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H, Huang GN, Cao YX, Zhong Y, Huang YH, Zhu GJ, Zhou LM, Chen ZJ, Shi JZ, Zeng Y, Weng N, Huang XF, Yang J, Zhu YM, Li YP, Yi D, Zhuang GL.
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov 01; 48(11):838-42. PubMed ID: 24444561
    [Abstract] [Full Text] [Related]

  • 17. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP, Macklon NS, Fauser BC.
    J Clin Endocrinol Metab; 2003 Jan 01; 88(1):166-73. PubMed ID: 12519847
    [Abstract] [Full Text] [Related]

  • 18. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
    Papanikolaou EG, Bourgain C, Kolibianakis E, Tournaye H, Devroey P.
    Hum Reprod; 2005 Jun 01; 20(6):1541-7. PubMed ID: 15705618
    [Abstract] [Full Text] [Related]

  • 19. Follicular atresia associated with concurrent initiation of gonadotropin-releasing hormone agonist and follicle-stimulating hormone for oocyte recruitment.
    Brzyski RG, Muasher SJ, Droesch K, Simonetti S, Jones GS, Rosenwaks Z.
    Fertil Steril; 1988 Dec 01; 50(6):917-21. PubMed ID: 3144467
    [Abstract] [Full Text] [Related]

  • 20. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization.
    Scott RT, Navot D.
    Fertil Steril; 1994 May 01; 61(5):880-5. PubMed ID: 8174725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.